Dr. David Veloso Lardizabal, MD

Dr. Lardizabal practices at Charleston Area Medical Center General Hospital in Charleston, West Virginia, part of Vandalia Health.

Dr. Lardizabal's NPI, 1265428593, was assigned on September 22, 2005. Dr. Lardizabal holds West Virginia license 32510.

Dr. Lardizabal's primary practice is Charleston Area Medical Center General Hospital, at 501 Morris Street, Charleston, WV 25301 in Kanawha County. The practice phone is (304) 388-5432.

Dr. Lardizabal's primary practice is Charleston Area Medical Center General Hospital in Charleston, West Virginia, part of Vandalia Health. Dr. Lardizabal is also affiliated with CAMC Greenbrier Valley Medical Center. The medical group on file is Charleston Area Medical Center. Dmand AI also links Dr. Lardizabal to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lardizabal practices, 3 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Lardizabal's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dmand AI has Dr. Lardizabal's licenses on file in 3 states: West Virginia, Michigan and Missouri.

CMS data shows 159 Medicare services from Dr. Lardizabal across 6 procedure codes in 2024, for 129 Medicare patients. Medicare paid $15,088 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 129 Medicare patients who saw Dr. Lardizabal in 2024. The largest group is 65 to 74, with 47 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 39% are also on Medicaid. Their average risk score is 1.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lardizabal's median patient age at 67, with 60% women.

In 2024, Dr. Lardizabal wrote 447 Medicare Part D claims for 77 patients. 85% of them were for generic drugs. CMS names the drug for 278 of them, across 10 drugs with 11 or more claims each, at $7,470 in total drug cost. In 2023, CMS named 15 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Lardizabal for performance year 2024, reported through an alternative payment model (APM). Dr. Lardizabal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lardizabal as offering telehealth.

Dmand AI links 3 papers to Dr. Lardizabal, published from 2012 to 2014. 2012 was the busiest year, with 2. Dr. Lardizabal's most frequent co-authors are Selim Ramin Benbadis, MD, Samden Dorjee Lhatoo, MD and Asim Mohammad Shahid, MD.

CMS Open Payments shows 31 general payments to Dr. Lardizabal from 7 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 81% of the total. Allergan Inc. paid the most, $9,485.